Home » Topics » Deals and M&A » Collaboration

Collaboration
RSS

European phase IIb study of Posidur meets primary endpoints

Feb. 10, 2011

Tacere Therapeutics reacquires Asian rights to RNAi-based agents targeting HCV

Feb. 10, 2011

Cepheid and FIND collaborate on Xpert HIV viral load test

Feb. 10, 2011

Circassia acquires worldwide rights to psoriasis and atopic dermatitis treatment PAP-1

Feb. 9, 2011

Biovail Labs acquires Canadian license for Aczone from Allergen

Feb. 9, 2011

Elan and Boehringer Ingelheim to codevelop antibody-based therapeutics

Feb. 9, 2011

Lundbeck is granted rights to several Cephalon products in Canada and Latin America

Feb. 8, 2011

Ansaris earns milestone payment from Ono Pharma with identification of kinase-related agent

Feb. 8, 2011

Optimer Pharma and Astellas enter agreement for antibiotic fidaxomicin

Feb. 8, 2011

Phosphagenics enters agreement to develop TPM-delivered antipsoriasis drug

Feb. 8, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Will Ovid’s golden age of KCC2 metamorph CNS?
BioWorld
The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in...
BMS-Hengrui deal strikes panic in Washington
BioWorld
On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar...